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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 3 g/day 
plant sterols/stanols and lowering blood LDL-cholesterol and reduced risk 
of (coronary) heart disease pursuant to Article 19 of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Unilever PLC and Unilever NV, submitted pursuant to Article 19 of 
Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on 
Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific 
substantiation of an application to modify the conditions of use of an authorised Article 14 claim 
related to 1.5 - 3.0 g plant sterols/stanols per day and lowering blood LDL-cholesterol by 7 - 12 % and 
reduced risk of (coronary) heart disease. The applicant has further requested that the minimum 
duration to obtain the effect be one to two weeks. The applicant provided a published systematic 
review and meta-analysis that evaluated the comparative efficacy of plant sterols and plant stanols for 
lowering blood LDL-cholesterol in healthy and hypercholesterolaemic subjects and an unpublished 
meta-analysis on 27 randomised controlled human studies on the LDL-lowering efficacy at a dose 
range between 2.6 and 3.4 g per day. On the basis of the data presented, the Panel concludes that plant 
sterols and stanol esters at daily intakes ranging from 1.5 to 3.0 g plant sterols/stanols in matrices 
approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise and salad 
dressings) have a similar efficacy on blood LDL-cholesterol lowering, that plant sterols and stanol 
esters at a daily intake of 3 g (range 2.6 g to 3.4 g) plant sterols/stanols in matrices approved by 
Regulation (EC) No 376/2010 lower LDL-cholesterol by 11.3 % (95 % CI: 10.0 - 12.5), and that the 
minimum duration required to achieve the maximum effect of plant sterols and stanols on LDL-
cholesterol lowering is two to three weeks.  
 
                                                     
1  On request from the Competent Authority of the United Kingdom following an application by Unilever PLC, Question No 
EFSA-Q-2011-01241, adopted on 26 April 2012. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Two members of the Panel did not participate in the discussion on the subject 
referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of 
interests. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, 
Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van 
Loveren, Hans Verhagen and EFSA‟s staff member Wolfgang Gelbmann for the preparatory work for this scientific 
opinion. 
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SUMMARY 
Following an application from Unilever PLC, submitted pursuant to Article 19 of Regulation (EC) No 
1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, 
Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of an 
application to modify the conditions of use of an Article 14 claim related to plant sterols/stanols and 
lowering blood LDL-cholesterol authorised by Regulation (EC) No 376/2010 amending Regulation 
(EC) No 983/2009 and Regulation (EC) No 384/2010. Specifically, the applicant has requested an 
extension of the conditions of use, i.e. the intake of 1.5 - 3.0 g/d of plant sterols/stanols leads to an 
LDL-cholesterol lowering effect of 7 – 12 % within one to two weeks. The application included a 
request for the protection of proprietary data. 
The applicant provided a published systematic review and meta-analysis that evaluated the 
comparative efficacy of plant sterols and plant stanols for lowering blood LDL-cholesterol in healthy 
and hypercholesterolaemic subjects. Trials were included in the analysis if they were randomised 
controlled trials directly comparing plant sterols versus plant stanols in healthy or 
hypercholesterolemic subjects and reported efficacy data suitable for calculation of the change from 
baseline. Both parallel and cross-over trials were eligible for inclusion. Based on data from 14 studies 
with 531 subjects, plant sterols and plant stanols at intakes ranging from 1.5 to 3.0 g/d in matrices 
approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise and salad 
dressings) were statistically not significantly different in lowering total cholesterol and LDL-
cholesterol. In one additional study not included in this meta-analysis no statistically significant 
differences in LDL-cholesterol lowering efficacy were found between plant sterols and stanols 
consumed in margarine at an intake of 2.5 g per day over 85 weeks.  
Related to the size of the effect, the applicant provided an unpublished meta-analysis on 27 
randomised controlled human studies on the LDL-lowering efficacy of  ≥ 2.6 to ≤ 3.4 g plant sterols 
or plant stanols per day in matrices approved by the European Commission. In this analysis the 
relative pooled LDL-cholesterol lowering effect was 11.3 % (95 % CI: 10.0 - 12.5). The Panel notes 
some limitations of the applicant‟s meta-analysis that contribute to uncertainty of the estimate of the 
LDL-cholesterol lowering effect, e.g. the study quality not being taken into account, limitations in the 
description of the random effects model applied by the applicant, and the estimation of relative net 
changes of LDL-cholesterol levels and variance parameters which were not reported in most of the 
original publications.  
The applicant claimed that the minimum duration required for efficacy was one to two weeks. In three 
of seven treatment arms, in which the earliest LDL-cholesterol measure was made after one week, the 
maximum LDL-cholesterol lowering effect was achieved already after one week of intervention, 
while in four other treatment arms LDL-cholesterol levels continued to decrease until treatment week 
two, three or four of the intervention. In seven out of seventeen treatment arms in which the earliest 
LDL-cholesterol measurement was made after two weeks of the intervention the maximum LDL-
cholesterol lowering effect was attained after two weeks of intervention, in another six treatment arms 
most of the reduction was already achieved after two weeks, while in four studies it took longer than 
two weeks before the maximum reduction was reached. The Panel considers that the minimum 
duration required to achieve the maximum effect of plant sterols and stanols on LDL-cholesterol 
lowering is two to three weeks. 
The Panel considers that plant sterols and stanol esters at daily intakes ranging from 1.5 to 3.0 g 
sterols/stanols in matrices approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy 
products, mayonnaise and salad dressings) have a similar efficacy on lowering blood LDL-
cholesterol.  
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The Panel concludes that plant sterols and stanol esters at a daily intake of 3 g (range 2.6 - 3.4 g) 
sterols/stanols in matrices approved by the Regulation (EC) No 376/2010 (yellow fat spreads, dairy 
products, mayonnaise and salad dressings) lower LDL-cholesterol by 11.3 % (95% CI: 10.0 – 12.5). 
The minimum duration required to achieve the maximum effect of plant sterols and stanols on LDL-
cholesterol lowering is two to three weeks. 
The Panel could have reached these conclusions without considering the unpublished meta-analysis 
claimed as proprietary by the applicant. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. Article 19 of this Regulation lays down 
provisions for the authorisation for modification, suspension and revocation of permitted health 
claims.  
STEPS TAKEN BY EFSA 
 The application was received on 15/12/2011. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. 
 The scientific evaluation procedure started on 10/01/2012. 
 On 18-20/01/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application, and the clock was stopped on 
23/01/2012 in compliance with Art. 16(1) of Regulation (EC) No 1924/2006.  
 On 01/02/2012, EFSA received the requested information as submitted by the applicant and 
the clock was restarted.  
 During its meeting on 25-27/04/2012, the NDA Panel, after having evaluated the overall data 
submitted, adopted an opinion on the scientific substantiation of a health claim related to 3 g 
plant sterols/stanols and lowering blood LDL-cholesterol by 12 % and reduced risk of 
(coronary) heart disease. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 19 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of an application to modify the conditions of use of an 
authorised Article 14 claim related to plant sterols/stanols and lowering blood LDL-cholesterol and 
reduced risk of (coronary) heart disease.  
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of plant sterols/stanols, a positive assessment of its safety, nor a decision on whether plant 
sterols/stanols are, or are not, classified as a foodstuff. It should be noted that such an assessment is 
not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 European Parliament and Council (2006). Regulation (EC) No 1924/2006 of the European Parliament and of the Council 
of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union OJ L 404, 
30.12.2006. Corrigendum OJ L 12, 18.1.2007, p. 3–18. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address:  
Unilever PLC: Port Sunlight, Wirral, Merseyside, CH62 4ZD, UK 
Unilever NV: Weena 455, Rotterdam, 3013 AL, NL 
The application indicates confidential and proprietary data. The applicant claims confidentiality and 
proprietary rights for an unpublished meta-analysis which has been conducted on published studies. 
Food/constituent as stated by the applicant 
Plant sterols (present as free sterols or sterol esters) as defined in Commission Decisions on 
authorizing the placing on the market of products with added plant sterols (2000/500/EC, 2004/333-
336/EC, 2004/845/EC, 2006/58-59/EC) and plant stanol esters [as defined in the Scientific Opinion of 
the Panel on Dietetic Products, Nutrition and Allergies related to the scientific substantiation of a 
health claim on plant stanol esters and lower/reduced blood cholesterol and reduced risk of (coronary) 
heart disease (EFSA, 2008a)]. In the context of this dossier, the term “phytosterols” is used as a 
generic term encompassing both the term plant sterols and plant stanols.  
Health relationship as claimed by the applicant 
The disease risk reduction claim regarding the LDL-cholesterol lowering effect of plant 
sterols/stanols, which is the subject of the proposed amendment on the conditions of use has received 
a positive opinion from the European Food Safety Authority (EFSA, 2008a, 2008b, 2009). 
Consequently, the European Commission authorised this claim to be used in consumer 
communications as laid down in Regulation (EC) No 983/2009 amended by Regulation (EC) No 
376/2010 and Regulation (EC) No 384/2010. More specific regarding the dose-response relationship, 
EFSA published that plant sterol/stanol intake of 1.5 - 2.4 g/d and blood LDL-cholesterol lowering of 
7 - 10.5 % in 2 – 3 weeks has been scientifically proven (EFSA, 2009), which is reflected in the EU 
authorisation decision in Regulations (EC) No 384/2010 and Regulations (EC) No 376/2010. New 
evidence has shown that an additional effect of up to 12 % is achieved with higher daily plant 
sterol/stanol intakes of up to 3 g/d. In addition, there is evidence that the minimum duration needed 
for plant sterols/stanols to exert a significant LDL-cholesterol lowering effect is 1 to 2 weeks. As 
such, the purpose of this dossier is to provide substantiation for an extension of the conditions of use: 
the intake of 1.5 - 3.0 g/d of plant sterols/stanols leads to an LDL-cholesterol lowering effect of 7 – 12 
% within 1 - 2 weeks. It is well established that elevated blood LDL-cholesterol is independently 
associated with an increased risk for coronary heart disease (CHD) and reduction in LDL-cholesterol 
is of importance and of benefit to individuals in the population with moderately elevated blood 
cholesterol concentrations. 
Wording of the health claim as proposed by the applicant 
“Plant sterols and plant stanol esters have been shown to lower/reduce blood cholesterol. High 
cholesterol is a risk factor in the development of coronary heart disease”.  
Specific conditions of use as proposed by the applicant 
The target population are people of the general population who need and want to lower their blood 
LDL-cholesterol concentrations. 
Consumers should be informed that the beneficial effect is obtained with a daily intake of 1.5 - 3.0 g 
plant sterols/stanols. Reference to the magnitude of the effect may only be made for foods within the 
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following categories: yellow fat spreads, dairy products, mayonnaise and salad dressings. When 
referring to the magnitude of the effect, the entire range „7 to 12 %‟ and the duration to obtain the 
effect „in 1 to 2 weeks‟ must be communicated to the consumer.  
The daily intake of 1.5 - 3.0 g of added plants sterols/stanols is attained through the use of either one 
portion containing a maximum of 3 g or three portions containing a maximum of 1 g per portion. 
As specified in Regulation (EC) No 608/2004: “There shall be an easily visible and legible statement 
that the product may not be nutritionally appropriate for pregnant and breastfeeding women and 
children under the age of five years”. 
As specified in Regulation (EC) No 608/2004. “There shall be a statement that the consumption of 
more than 3 g per day of added plant sterols/plant stanols should be avoided” 
As specified in Regulation (EC) No 608/2004: “There shall be a statement that patients on cholesterol 
lowering medication should only consume the product under medical supervision”. 
As specified in Regulation (EC) No 608/2004: “Advice shall be included that the product should be 
used as part of a balanced and varied diet, including regular consumption of fruit and vegetables to 
help maintain carotenoid levels. 
ASSESSMENT 
1. INTRODUCTION  
The applicant has proposed to change the conditions of use for claims made on food products with 
added plant sterols and plant stanols as authorized by Regulation (EC) No 376/2010 amending 
Regulation (EC) 983/2009 and Regulation (EC) No 384/2010. The authorised claim is: „Plant sterols 
and plant stanol esters have been shown to lower/reduce blood cholesterol. High cholesterol is a risk 
factor in the development of coronary heart disease.‟ The conditions of use of the claim are: 
„Information to the consumer that the beneficial effect is obtained with a daily intake of 1.5 – 2.4 g 
plant sterols/stanols.  Reference to the magnitude of the effect may only be made for foods within the 
following categories: yellow fat spreads, dairy products, mayonnaise and salad dressings. When 
referring to the magnitude of the effect, the entire range „7 to 10 %‟ and the duration to obtain the 
effect „in 2 to 3 weeks‟ must be communicated to the consumer‟. 
Specifically, the applicant has requested an extension of the conditions of use, i.e. the intake of 1.5 – 
3.0 g per day of plant sterols/stanols leads to an LDL-cholesterol lowering effect of 7 – 12 % within 1 
- 2 weeks.  
The Panel recalls the conclusions from its earlier opinion on plant sterols/stanols and lowering LDL-
cholesterol (EFSA, 2009) that (i) the efficacy for lowering LDL-cholesterol is similar for plant sterols 
and plant stanols, that (ii) 1.5 - 1.9 g and 2.0 - 2.4 g plant sterols/plant stanols per day was observed to 
lower blood LDL-cholesterol by an average of 8.5 % and 8.9 %, respectively, and that for an intake of 
1.5 - 2.4 g/d an average reduction of between 7 and 10.5 % can be expected, that (iii) the blood LDL 
cholesterol lowering effect is usually established within the first 2 - 3 weeks and can be sustained by a 
continued consumption of plant sterols/stanols, and that (iv) while plant sterols/stanols added to foods 
such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, 
yoghurts and cheese have been shown consistently to lower blood LDL-cholesterol, the efficacy of 
plant sterols/stanols added to other food formats is less well established. 
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This opinion focuses on the efficacy of 3.0 g/d of plant sterols/stanols on LDL-cholesterol lowering 
and on the minimum duration for the effect to occur. 
Throughout this opinion, quantities of sterols and stanol esters are expressed as the equivalent 
weights of free [i.e. un-esterified] sterols and stanols. 
2. SIMILARITY OF BLOOD LDL-CHOLESTEROL LOWERING EFFECTS OF PLANT STEROLS AND 
PLANT STANOLS 
The applicant provided a published systematic review and meta-analysis that evaluated the 
comparative efficacy of plant sterols and plant stanols for lowering blood LDL-cholesterol in healthy 
and hypercholesterolemic subjects (Talati et al., 2010). Trials were included in the analysis if they 
were randomised controlled trials directly comparing plant sterols versus plant stanols in healthy or 
hypercholesterolemic subjects and reported efficacy data suitable for calculation of the change from 
baseline. Both parallel and cross-over trials were eligible for inclusion. The weighted mean difference 
of the change from baseline with the 95 % confidence interval was calculated as the difference 
between the means in the plant sterol and plant stanol groups using a random-effects model. Based on 
data from 14 studies with 531 subjects, plant sterols and plant stanols at intakes ranging from 1.5 to 
3.0 g/d in matrices approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, 
mayonnaise and salad dressings) were statistically not significantly different in lowering total 
cholesterol (difference: -1.11 mg/dL; 95 % CI: -4.12 to 1.90; p = 0.47) and LDL-cholesterol 
(difference: -0.35 mg/dL; 95 % CI: -2.98 to 2.28; p = 0.79). Four studies included in this meta-
analysis used intakes higher than 2 g/d (but not exceeding 3 g/d) and showed comparable effects in 
lowering total and LDL-cholesterol for plant sterols and stanols without evidence for a difference in 
the efficacy between sterols and stanols (de Jong et al. 2008a; Nestel et al. 2001; Noakes et al. 2002; 
Weststrate et al. 1998).  
In another study (de Jong et al., 2008b), not included by Talati et al. (2010), the long-term efficacy of 
plant sterols and stanols was investigated in a double-blind, randomized, placebo-controlled parallel 
trial comparing a margarine enriched with 2.5 g/d plant sterols or 2.5 g/d plant stanols versus a control 
margarine over 85 weeks with in total 54 subjects. No statistically significant differences in LDL-
cholesterol lowering efficacy were found between plant sterols and stanols at 45 weeks (11.6 % and 
8.7 % for plant sterols and stanols, respectively) and at the end of the intervention period at 85 weeks 
(8.7 % and 13.1 % for plant sterols and stanols, respectively). 
The Panel considers that the evidence from randomised controlled human intervention studies which 
directly compared the efficacy of plant sterols and stanol esters at daily intakes ranging from 1.5 to 
3.0 g sterols/stanols in matrices approved by Regulation (EC) No 376/2010 shows that plant sterols 
and stanols at intakes up to 3 g per day have a similar efficacy on lowering blood LDL-cholesterol.  
3. BLOOD LDL-CHOLESTEROL LOWERING EFFECT OF A DAILY INTAKE OF 3 G  PLANT 
STEROLS/STANOLS 
In order to find pertinent studies for inclusion into a meta-analysis to study the effect size, the 
applicant relied on the systematic searches performed by the authors of two recent meta-analyses 
(Demonty et al., 2009; Musa-Veloso et al., 2011) who used almost identical search strategies. 
Demonty et al. (2009) searched 5 databases (Medline, Cab Abstracts, Biological Abstracts, Web of 
Science, and the Cochrane Library) through July 2007. Keywords related to plant sterols and stanols 
(phytosterols), sitosterol, sitostanol, campesterol, campestanol, stigmasterol, brassicasterol, blood 
lipids, cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. Musa-Veloso et al. (2011) 
searched 16 databases (Medline, Cab Abstracts, Allied & Complementary Medicine, Mantis, Pascal, 
Foodline: Science, Global Health, Biosis Previews, Elsevier Biobase, National Technical Information 
Service, Gale Group Health & Wellness Database, Embase, New England Journal of Medicine, Adis 
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Clinical Trials Insight, Web of Science, and the Cochrane Library) through November 2010, and used 
identical search terms to those described by Demonty et al. (2009). Both searches were limited to 
human studies. There was no restriction on publication date or language.  
An additional search was performed by the applicant using 9 databases (Medline, Embase, Biosis, 
Cab Abstracts, FROSTI, Food Science & Technology Abstracts, Chemical Abstracts, Pascal, 
Agricola) from September 2010 through September 2011 using similar selection criteria as for the 2 
recent meta-analyses (Demonty et al. 2009; Musa-Veloso et al. 2011). The inclusion criteria were: 
randomized controlled trial within human adults (parallel-arm or cross-over trials); treatment with 
“usual phytosterols”, where “usual phytosterols” was defined as 4- desmethylsterols and/or 4-
desmethylstanols extracted from vegetables or plant oils such as soybean oil, rapeseed oil and tall oil; 
blood lipids as primary or secondary outcomes; and absence of a co-intervention from which 
consumption of phytosterol-enriched foods or supplements could not be isolated. The exclusion 
criteria were: not a randomized controlled trial; relevant blood lipid data missing; phytosterols 
consumed for less than 2 weeks; control group did not receive a placebo; ferulated phytosterols such 
as rice bran oil and shea nut oil sterols were used; colectomised patients were part of the study; and 
dose of phytosterols > 3.8 g per day. On request by EFSA, the applicant limited the dose range for 
studies pertinent to this claim to ≥ 2.6 to ≤ 3.4 g phytosterols per day.  
In total, 29 (19 stanol and 10 sterol) treatment arms were identified which studied doses of ≥ 2.6 to ≤ 
3.4 g plant sterols or stanols per day without limitation with regard to the food format (unpublished 
meta-analysis, Unilever, 2011). The food formats used were margarine or spreads in 24 studies, 
yoghurts in two studies, and mayonnaise, ground beef and muffin/croissant  in one study each. The 
latter two trials (with ground beef and muffin/croissant as food matrix) were excluded when only 
studies were considered which used food formats specified in Regulation (EC) No 376/2010. With 
this restriction the applicant‟s selection resulted in 19 stanol (11 parallel/8 cross-over trials) and 8 
sterol (3 parallel/5 cross-over trials) arms. The main outcome variable was the relative net change in 
LDL-cholesterol. When the outcome variable was measured at various time points during the 
intervention, the value corresponding to, or closest to, the 4-week time point was taken for the 
analysis. When relative net changes were reported, these values were collected. For studies in which 
relative net changes were not reported, they were calculated from the absolute changes. A pooled 
estimate of the relative LDL-cholesterol lowering effect of phytosterols was calculated using a 
random effects model according to the methods described by DerSirmonian and Laird (1986) in order 
to take into account the large variation in LDL-cholesterol lowering effects observed between studies. 
Several studies did not report the relative (%) net change and most of the studies did not report 
variance parameters for the relative change. For the weighting of the studies the applicant used the 
number of subjects. For cross-over studies, the weight was defined as the total number of subjects 
included, whilst for the parallel studies, the weight was defined as half of the total number of subjects 
included. The pooled estimates and accompanying 95 % CIs were determined using a mixed statistical 
procedure for analyses of variances (SAS version 9.2). In this analysis among 27 treatment arms 
which used the matrices margarine and other spreads, dressing and yoghurt as specified in the 
Commission Regulation, the relative pooled LDL-cholesterol lowering effect was 11.3 % (95 % CI: 
10.0 - 12.5). 
The Panel notes some limitations of the applicant‟s meta-analysis that contribute to uncertainty of the 
estimate of the LDL-cholesterol lowering effect. Study quality was not taken into account on the basis 
that from the meta-analysis of Demonty et al. (2009) with 141 treatment arms it was concluded that 
study quality did not influence the dose-response for plant sterols and stanols. The Panel considers 
that this conclusion cannot be extrapolated to a small subset of studies included in the unpublished 
meta-analysis by the applicant. The Panel also notes the limitations in the description of the random 
effects model applied by the applicant. Uncertainties derive also from the estimation of relative (%) 
net changes of LDL-cholesterol levels and variance parameters which were not reported in most of the 
original publications.  
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The Panel notes that the results of this unpublished meta-analysis provided by the applicant are 
comparable to the results of the published meta-analysis by Katan et al. (2003) which showed a 
pooled mean reduction of LDL-cholesterol levels of 11.3 % (95 % CI: 10.2 - 12.3) for ≥ 2.5 g 
phytosterols consumed daily. The meta-analysis by Katan et al. (2003) comprised 21 treatment arms 
(13 stanol arms, 8 sterol arms; average dose 3.0 g) from five studies with doses between 2.5 and 2.9 g, 
13 studies with doses between 3.0 and 3.4 g, and two studies with 4.0 and 4.2 g phytosterols, 
respectively). 
The Panel considers that the evidence from randomised controlled human intervention studies of plant 
sterols and stanol esters at a daily intake of 3 g (range 2.6 - 3.4 g) plant sterols/stanols in matrices 
approved by Regulation (EC) No 376/2010 shows an average pooled LDL-cholesterol reduction of 
11.3 % (95% CI: 10.0 – 12.5). 
The Panel could have reached this conclusion without considering the unpublished meta-analysis 
claimed as proprietary by the applicant. 
4. MINIMUM DURATION FOR EFFECT OF PLANT STEROLS/STANOLS 
The applicant claims that the minimum duration required for efficacy was one to two weeks. In three 
(Mensink et al., 2002; plant stanols; Noakes et al., 2005, plant sterol and plant stanol arm) of seven 
treatment arms, in which the earliest LDL-cholesterol measurement was made after one week, the 
maximum LDL-cholesterol lowering effect was achieved already after one week of intervention. In 
the four other treatment arms LDL-cholesterol levels continued to decrease in week two (Jones et al., 
2000, plant stanol arm), week three (Jones et al., 2000, plant sterol arm; Mussner et al., 2002, plant 
sterols) and week four (Goldberg et al., 2006, plant stanols) of the intervention. The Panel considers 
that the maximum LDL-cholesterol reduction is not generally attained after one week of intervention 
with plant sterols and stanols. 
In seven (Blair et al., 2000; Gonzales et al., 2007; Homma et al., 2003, treatment arms 1 and 2; Maki 
et al., 2001, treatment arm 1; Niittynen et al., 2007; Nguyen et al., 1999, treatment arm 1) out of 17 
treatment arms in which the earliest LDL-cholesterol measurement was made after two weeks of the 
intervention, the maximum LDL-cholesterol lowering effect was already attained after 2 weeks of the 
intervention; in another six (Hallikainen and Uusitupa, 1999, treatment arms 1 and 2; Maki et al., 
2001, treatment arm 2; Nguyen et al., 1999, treatment arms 2 and 3; Seki et al., 2003a) of these 17 
treatment arms most of the reduction was already achieved after two weeks. In the four remaining 
studies (Matvienko et al., 2002; Deveraj et al., 2004; Saito et al., 2006; Seki et al., 2003b) it took 
longer than two weeks before the maximum  reduction was reached.  
The Panel notes that in most of the studies blood LDL-cholesterol was measured for the first time 
only after two or three weeks of intervention, when the full effect has usually been established. The 
Panel considers that there is insufficient evidence to conclude that the maximum effect is generally 
achieved already after one week, and refers to its previous opinion from 2009 when it concluded that 
the blood LDL-cholesterol lowering effect is usually established within the first two to three weeks of 
consumption of stanols/sterols (EFSA, 2009).  
The Panel considers that the minimum duration required to achieve the maximum effect of plant 
sterols and stanol esters on LDL-cholesterol lowering is two to three weeks. 
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CONCLUSIONS  
Plant sterols and stanol esters at daily intakes ranging from 1.5 to 3.0 g sterols/stanols in matrices 
approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise and salad 
dressings) have a similar efficacy on lowering blood LDL-cholesterol.  
Plant sterols and stanol esters at a daily intake of 3 g (range 2.6 - 3.4 g) sterols/stanols in matrices 
approved by the Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise and 
salad dressings) lower LDL-cholesterol by 11.3 % (95% CI: 10.0 – 12.5). 
The minimum duration required to achieve the maximum effect of plant sterols and stanol esters on 
LDL-cholesterol lowering is two to three weeks. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on plant sterols and stanols and blood cholesterol pursuant to Article 19 of 
Regulation (EC) No 1924/2006 (Claim serial No: 0316_UK). November 2011. Submitted by Unilever 
PLC (UK) and Unilever NV (NL). 
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GLOSSARY / ABBREVIATIONS 
CHD  Coronary heart disease 
LDL  Low density lipoproteins 
